ASCO 2015 - Prostate Cancer

CHICAGO, IL USA (UroToday.com) - Dr. Gillian Duchesne, a radiation oncologist from the Peter MacCallum Cancer Center in Melbourne, Australia, presented the initial results of the TOAD study, a phase III randomized clinical trial assessing the timing of androgen deprivation therapy (ADT) among asymptomatic men with biochemical recurrence of prostate cancer.

CHICAGO, IL USA (UroToday.com) - Dr. Howard Sandler of Cedars-Sinai presented the results of RTOG 0521. The study sought to improve outcomes associated with treatment of locally advanced or high-risk localized prostate cancers that traditionally have a high risk of recurrence despite the use of standard of care radiotherapy and 2-3 years of concurrent androgen deprivation therapy (ADT).

CHICAGO, IL USA (UroToday.com) - Adding docetaxel to standard hormone and radiation therapy reduced the risk of death for men with high-risk, localized prostate cancer in results reported at the 2015 ASCO Annual Meeting, in Chicago, IL.  At a median follow-up of 5.5 years in this phase III study RTOG 0521, overall survival (OS) rates were 93% in the docetaxel-treated group vs. 89% in the standard therapy group.

CHICAGO, IL USA (UroToday.com) - Dr. Nicholas James presented the initial survival results from the STAMPEDE study of men with metastatic or biochemical recurrent hormone sensitive prostate cancer.

CHICAGO, IL USA (UroToday.com) - Dr. Howard Scher of Memorial Sloan Kettering presented the Prostate Cancer Working Group 3 (PCWG3) Consensus Guidelines, an update from the previously published Prostate Cancer Working Group 2 (PCWG2) set published in 2008.

CHICAGO, IL USA (UroToday.com) - Along with evidence of the long-term efficacy and safely of a novel oral androgen receptor -- ODM-201^[1] – details of the launch of a phase 3 study, now open and recruiting, were presented at the 2015 ASCO Annual Meeting, in Chicago, IL.

CHICAGO, IL USA (UroToday.com) - The novel, oral, high-affinity inhibitor of the androgen receptor, ODM-201, was shown to possess high anticancer activity and a favorable tolerability profile in long-term results from the international phase I/II ARADES study, with data at 38 weeks that were consistent with earlier-reported 12-week efficacy and safety among progressive mCRPC patients.^[1]